Virosome studied by MedImmune

By Dylan Bushell-Embling
Friday, 18 July, 2008

Technology developed by Norwood Abbey's [ASX: NAL] second-tier subsidiary Virosome Biologicals is being evaluated by US company MedImmune.

The companies have signed a six-month exclusive evaluation agreement over Virosome's virosomal vaccine technology. In this time the companies will collaborate on research using the virosome technology with MedImmune vaccine candidates.

MedImmune is a member of the AstraZeneca group.

Defective sperm doubles pre-eclampsia risk in IVF patients

A high proportion of the father's spermatozoa possessing DNA strand breaks is associated with...

Free meningococcal B vaccines coming to the NT

The Northern Territory Government has confirmed the rollout of a free meningococcal B vaccine...

Mouth bacteria linked to increased head and neck cancer risk

More than a dozen bacterial species that live in people's mouths have been linked to a...

Content from other channels on our network

Burnet, Atomo to jointly develop active syphilis self-test

My Health Record: ADHA seeks industry input on support, maintenance

Monash, Optiscan partner to develop AI-powered endoscopes

Review proposes major health system changes

Private Health CEO Forum to tackle financial viability issues

Custom Denning achieves first pantograph fast-charging electric bus

Orica cuts particle emissions from Kooragang Island site by 95%

Air-gapped networks give a false sense of security

BHP strengthens partnership with ABB

Seamless modular I/O integration

SA project uses Cement Australia's low-carbon tech

Data centres working to use water responsibly

Orica cuts particle emissions from Kooragang Island site by around 95%

CSIRO's new facility for printed flexible solar techology

Driving change: how electric vehicles are fuelling Australia's sustainable businesses